Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, January 30, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Joel Beatty Maintained (BMRN) at Buy with Decreased Target to $104 on, Jan 30th, 2024
Joel Beatty of Baird, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Decreased Target from $127 to $104 on, Jan 30th, 2024.
Joel has made no other calls on BMRN in the last 4 months.
There are 8 other peers that have a rating on BMRN. Out of the 8 peers that are also analyzing BMRN, 2 agree with Joel's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Luca Issi of "RBC Capital" Reiterated at Hold and Held Target at $100 on, Tuesday, November 7th, 2023
- William Pickering of "Bernstein" Upgraded from Sell to Hold and Held Target at $82 on, Monday, October 23rd, 2023
These are the ratings of the 6 analyists that currently disagree with Joel
- Paul Matteis of "Stifel" Reiterated at Strong Buy and Held Target at $101 on, Thursday, December 21st, 2023
- Kostas Biliouris of "BMO Capital" Maintained at Buy with Decreased Target to $100 on, Friday, November 3rd, 2023
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $117 on, Thursday, November 2nd, 2023
- Olivia Brayer of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $100 on, Thursday, November 2nd, 2023
- Christopher Raymond of "Piper Sandler" Maintained at Buy with Decreased Target to $115 on, Thursday, November 2nd, 2023
- Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $111 on, Thursday, November 2nd, 2023
